These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

698 related items for PubMed ID: 14676105

  • 1. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [Abstract] [Full Text] [Related]

  • 2. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 01; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 3. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.
    Wong JY, Somlo G, Odom-Maryon T, Williams LE, Liu A, Yamauchi D, Wu AM, Yazaki P, Wilczynski S, Shively JE, Forman S, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3224s-3231s. PubMed ID: 10541368
    [Abstract] [Full Text] [Related]

  • 4. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.
    Wong JY, Williams LE, Yamauchi DM, Odom-Maryon T, Esteban JM, Neumaier M, Wu AM, Johnson DK, Primus FJ, Shively JE.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5929s-5934s. PubMed ID: 7493373
    [Abstract] [Full Text] [Related]

  • 5. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY, Thomas GE, Yamauchi D, Williams LE, Odom-Maryon TL, Liu A, Esteban JM, Neumaier M, Dresse S, Wu AM, Primus FJ, Shively JE, Raubitschek AA.
    J Nucl Med; 1997 Dec 01; 38(12):1951-9. PubMed ID: 9430476
    [Abstract] [Full Text] [Related]

  • 6. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
    Behr TM, Memtsoudis S, Vougioukas V, Liersch T, Gratz S, Schmidt F, Lorf T, Post S, Wörmann B, Hiddemann W, Ringe B, Becker W.
    Anticancer Res; 1999 Dec 01; 19(4A):2427-32. PubMed ID: 10470170
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
    Wong JY, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Raubitschek AA.
    Cancer Biother Radiopharm; 2006 Apr 01; 21(2):88-100. PubMed ID: 16706629
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 01; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 10. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY, Chu DZ, Yamauchi D, Odom-Maryon TL, Williams LE, Liu A, Esteban JM, Wu AM, Primus FJ, Beatty JD, Shively JE, Raubitschek AA.
    J Nucl Med; 1998 Dec 01; 39(12):2097-104. PubMed ID: 9867150
    [Abstract] [Full Text] [Related]

  • 11. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
    Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF.
    Clin Cancer Res; 2002 Sep 01; 8(9):2806-11. PubMed ID: 12231520
    [Abstract] [Full Text] [Related]

  • 12. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL, Pedley RB, King DJ, Green AJ, Yarranton GT, Begent RH.
    Br J Cancer; 1999 Nov 01; 81(6):972-80. PubMed ID: 10576653
    [Abstract] [Full Text] [Related]

  • 13. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 14. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
    Juweid M, Swayne LC, Sharkey RM, Dunn R, Rubin AD, Herskovic T, Goldenberg DM.
    Gynecol Oncol; 1997 Dec 01; 67(3):259-71. PubMed ID: 9441773
    [Abstract] [Full Text] [Related]

  • 15. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS, Mangalik A, Ferguson J, Elias L.
    Clin Cancer Res; 1995 Jun 01; 1(6):615-20. PubMed ID: 9816023
    [Abstract] [Full Text] [Related]

  • 16. Continuous infusion chemotherapy as a radiation-enhancing agent for yttrium-90-radiolabeled monoclonal antibody therapy of a human tumor xenograft.
    Remmenga SW, Colcher D, Gansow O, Pippen CG, Raubitschek A.
    Gynecol Oncol; 1994 Oct 01; 55(1):115-22. PubMed ID: 7959251
    [Abstract] [Full Text] [Related]

  • 17. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
    Vuillez JP, Kraeber-Bodéré F, Moro D, Bardiès M, Douillard JY, Gautherot E, Rouvier E, Barbet J, Garban F, Moreau P, Chatal JF.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3259s-3267s. PubMed ID: 10541373
    [Abstract] [Full Text] [Related]

  • 18. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
    Mittal BB, Zimmer MA, Sathiaseelan V, Benson AB, Mittal RR, Dutta S, Rosen ST, Spies SM, Mettler JM, Groch MW.
    Cancer; 1996 Nov 01; 78(9):1861-70. PubMed ID: 8909304
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans.
    Odom-Maryon TL, Williams LE, Chai A, Lopatin G, Liu A, Wong YC, Chou J, Clarke KG, Raubitschek AA.
    J Nucl Med; 1997 Dec 01; 38(12):1959-66. PubMed ID: 9430477
    [Abstract] [Full Text] [Related]

  • 20. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
    Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A, Goldenberg DM.
    J Nucl Med; 2005 Apr 01; 46(4):620-33. PubMed ID: 15809485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.